![Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial](https://oncodaily.com/pub/uploads/2024/08/Beckermann_Katy_Eby_web-223x300-1-e1725014978778.png)
Photo taken from medschool.vanderbilt.edu
Aug 30, 2024, 16:32
Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial
Katy Beckermann, Assistant Professor Of Medicine, Vanderbilt University Medical Center, shared a post on X:
“Congrats to Moshe Ornstein, MD and team for demonstrating the feasibility of an intermittent ipi/nivo approach in their Phase II trial, showing potential for prolonged treatment-free intervals. Looking forward to more studies like this.”
Authors: Moshe C. Ornstein, Laeth George, Wei Wei, C. Marcela Diaz-Montero, Pat Rayman, Allison Martin, Arnab Basu, Kathryn E.
Beckermann, Amanda Nizam, Christopher E. Wee, Timothy D. Gilligan, Shilpa Gupta, Brian I. Rini
![Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial 2 Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial](https://oncodaily.com/pub/uploads/2024/08/Screenshot-2024-08-30-155926-800x219.png)
a
Academic clinical trials
Allison Martin
Amanda Nizam
Arnab Basu
Brian I. Rini
C. Marcela Diaz-Montero
cancer
Christopher E. Wee
Kathryn E. Beckermann
Katy Beckermann
Laeth George
Moshe C. Ornstein
Moshe Ornstein
OncoDaily
Oncology
Pat Rayman
Shilpa Gupta
Timothy D. Gilligan
Vanderbilt University Medical Center
Wei Wei